Comparative Pharmacology
Head-to-head clinical analysis: NEO CORTEF versus NEO DELTA CORTEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO CORTEF versus NEO DELTA CORTEF.
NEO-CORTEF vs NEO-DELTA-CORTEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Hydrocortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Corticosteroid with potent anti-inflammatory, immunosuppressive, and antiallergic effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Apply a thin layer to the affected area 3 to 4 times daily. Use the 0.5% strength for mild conditions and 1% for more severe conditions.
1-2 drops into the conjunctival sac every 1-2 hours during the day and every 2 hours at night initially, then reduce frequency as inflammation subsides.
None Documented
None Documented
Terminal half-life 2-4 hours for neomycin; hydrocortisone half-life 1-2 hours. Clinical context: q6-8h dosing.
Prednisolone: 2-4 hours; clinical context: adrenal suppression lasts 24-36 hours, requiring tapering
Renal (70-80% as free drug and metabolites), fecal (20-30% via bile).
Renal: 70-80% as metabolites; biliary: 10-15%; fecal: <5%
Category C
Category C
Corticosteroid with Antibiotic
Corticosteroid with Antibiotic